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Abstract Angiotensin-I-converting enzyme (ACE) inhibitory
activity of a tryptic digest of bovine KS2-casein (KS2-CN) was
extensively investigated. Forty-three peptide peaks were isolated
and tested. Seven casokinins (i.e. CN-derived ACE inhibitory
peptides) were identi¢ed and their IC50 values were determined.
Four peptides exhibited an IC50 value lower than 20 WM. Pep-
tides KS2-CN (f174^181) and KS2-CN (f174^179) had IC50 val-
ues of 4 WM. Surprisingly, deletion of the C-terminal dipeptide
of two of these casokinins did not signi¢cantly alter their inhib-
itory activity.
1 2002 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Angiotensin-I-converting enzyme (ACE, EC 3.4.15.1) has a
key role in blood pressure regulation. It principally catalyses
the conversion of angiotensin I into angiotensin II, a powerful
endogenous vasoconstrictor; ACE also degrades the vasodila-
tor bradykinin. ACE is a Zn2þ metallopeptidase also called
peptidyl dipeptidase A because of its main speci¢city [1]. This
enzyme anchored in the cellular membrane can appear under
two isoforms: a somatic form (1277 amino acids for the ma-
ture human ACE) found in endothelial, epithelial and neuro-
nal cells and a smaller testicular form. The somatic form
contains an amino and a carboxyl domain that exhibit 60%
homology, suggesting a gene duplication; these two domains
have their own speci¢c catalytic site, independently working.
Inhibitors of ACE (captopril, benazepril, enalapril, lisino-
prilT) are used in therapy against hypertension. ACE inhibi-
tors reduce short-term and long-term morbidity and mortality
of hypertensive patients su¡ering from diabetes, renal insu⁄-
ciency or heart failure thanks to their renoprotective and vas-
culoprotective e¡ects [2,3].
During the two last decades an increasing number of data
have evidenced that milk has more functions than only ener-
getic and nutritional ones. Some peptides released from milk
proteins by gastric and/or pancreatic enzymes might act as
physiological regulators [4,5]. Peptides identi¢ed in milk pro-
tein hydrolysates have putative opioid, mineral carrier, anti-
microbial, antithrombotic, immunomodulator, anxiolytic or
antihypertensive bioactivity [6^8]. Many ACE inhibitors
have been isolated in enzymatic digest from food proteins
[9] and especially from milk proteins [9^12]. For some of
them, an antihypertensive activity has been characterised in
vivo by measuring the decrease of systolic blood pressure in
humans or in spontaneously hypertensive rats [13].
Digestive enzymes are often used to produce functional or
bioactive peptides. Trypsin, which is quantitatively present in
human neonates as well as in adults, appears to be appropri-
ate to search ACE inhibitory peptides as no particular amino
acid sequence seems to be required for this activity and as
such peptides have already been obtained with this enzyme
[14^17]. Numerous bioactive peptides have been identi¢ed in
bovine milk hydrolysates, especially in KS1-, L-, U-caseins
(CNs), while KS2-CN was less studied because of its poor
solubility and because of puri¢cation di⁄culties. KS2-CN ac-
counts for about 10% of the bovine CNs; variant A is wide-
spread in Bos taurus [18]. To date, antimicrobial [19^20] and
ACE inhibitory [21] peptides have been identi¢ed in bovine
KS2-CN. The latter peptides weakly inhibit ACE: KS2-CN
(f189^193), KS2-CN (f189^197), KS2-CN (f190^197) and KS2-
CN (f198^202) have 580, 600, 300 and 400 WM IC50 values
respectively. They have not shown signi¢cant activity during
in vivo experiments [21].
The present work was undertaken to identify and character-
ise, in an extensive way, the tryptic peptides from bovine KS2-
CN that e⁄ciently inhibited ACE.
2. Materials and methods
2.1. Enzymes and other reagents
L-1-Tosylamide-2-phenylethyl chloromethyl ketone (TPCK) treated
insoluble trypsin from bovine pancreas (E.C. 3.4.21.4) attached to
beaded agarose and angiotensin converting enzyme from rabbit lung
tissue (EC 3.4.15.1) were obtained from Sigma, (St. Louis, MO,
USA). Hippuryl-His-Leu-OH (HHL) was obtained from Bachem (Bu-
bendorf, Switzerland). Captopril was from Sigma (St. Louis, MO,
USA). Peptides were synthesised by Neosystem (Strasbourg, France).
Others reagents were of analytical grade.
2.2. Puri¢cation of bovine KS2-CN
Bovine KS2-CN variant A was puri¢ed by a cationic exchange chro-
matography followed by a hydrophobic interaction chromatography
as previously described [22].
2.3. Tryptic hydrolysis
Bovine KS2-CN (0.5 mg ml31) was incubated for 24 h at 37‡C with
immobilised trypsin (0.1 NK-benzoyl-L-arginine ethyl ester unit ml31)
in 67 mM sodium phosphate bu¡er, pH 8.1. The reaction was stopped
by centrifugation (2500Ug, 6 min, 4‡C).
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Fig. 1. RP-HPLC pro¢le (a) and ACE inhibitory activity (b) of tryptic hydrolysate from bovine KS2-CN. Separation was performed on a C18
column at 37‡C. A quantity of 250 Wg of sample (0.5 mg/ml) were injected. Flow rate was 1 ml/min. Numbers refer to peptide peaks tested.
Remaining ACE activity was determined in duplicate (except *, only once) after a 60 min incubation at 37‡C in a 50 mM CHES bu¡er, pH
8.3, containing 5 mM HHL, 350 mM NaCl, 3.33 U/l ACE and 50 WM in primary amines of potential inhibitor. Released hippuric acid was
quanti¢ed at 228 nm after separation by RP-HPLC onto C18 column. Inhibition percentage was calculated by comparison with a control with-
out peptide peak.
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2.4. Peptides puri¢cation
Separation of the peptides from the tryptic digest of bovine KS2-CN
was performed by RP-HPLC onto a XTerra1 (Waters, Milford, MA,
USA) C18 column (4.6 mm i.d.U250 mm) kept at 37‡C and con-
nected to a Waters HPLC model Alliance 2690. Samples (0.5 mg
ml31) were ¢ltered through 0.45 Wm PVDF ¢lters (Gelman Labora-
tory, Ann Harbor, MI, USA) and 250 Wg were injected. After a 3 min
isocratic elution (1.6% acetonitrile in 0.1% TFA), a linear gradient
from 1.6% to 40% acetonitrile in 0.1% TFA was applied in 87 min
at a £ow rate of 1 ml min31. Detection was performed between 210
and 300 nm with a Waters 996 photodiode array detector. Peptides
were collected and lyophilised.
2.5. Peptides quanti¢cation
Peptides were quanti¢ed with the OPA (o-phthaldialdehyde) meth-
od [23] adapted by Frister et al. [24] with some modi¢cations: mea-
surements were taken after a 3 min reaction time at room temperature
and lyophilised peptides and leucine standards were solubilised in
7.5% (v/v) ethanol.
2.6. Peptide identi¢cation
Peptides from the tryptic digest have been identi¢ed by amino acid
composition and mass spectrometry [22]. Sequence of the peptides
selected for IC50 determination was checked again by Edman micro-
sequencing with a model 476A microsequencer (Applied Biosystems,
Foster City, CA, USA) before their chemical synthesis.
2.7. Determination of ACE inhibition
The method used was adapted from Cushman and Cheung [25]:
ethyl-acetate extraction of hippuric acid was replaced by its RP-HPLC
separation. A quantity of 140 Wl of 50 mM CHES bu¡er, pH 8.3,
containing 5 mM HHL, 350 mM NaCl and appropriate concentra-
tions of KS2-CN peptide dissolved in 5% (v/v) EtOH was preincubated
10 min at 37‡C. 10 Wl of ACE (3.33 U l31) was added and the mixture
was incubated 60 min at 37‡C. A control was realised without KS2-CN
peptide. The reaction was stopped with captopril, trisodic EDTA and
tri£uoroacetic acid at 5 WM, 1 mM and 0.067% (v/v) ¢nal concentra-
tions respectively. Released hippuric acid was quanti¢ed by RP-HPLC
onto a Symmetry0 (Waters, Milford, MA, USA) C18 column (2.1
mm i.d.U150 mm) kept at 37‡C. The column was connected to a
Waters HPLC model Alliance 2690. Samples were ¢ltered through
0.45 Wm PVDF ¢lters and 40 Wl were injected. A linear gradient
from 13 to 50% acetonitrile in 0.1% TFA was applied in 7 min,
then 99% acetonitrile in 0.1% TFA was reached in 0.5 min; this
proportion was maintained during 1.5 min. Flow rate was 0.25 ml
min31. Detection was performed at 228 nm with a Waters 996 photo-
diode array detector.
ACE inhibitory activity of each chromatographic peptide peak
from the hydrolysate was tested twice at 50 WM primary amines to
discriminate the most e⁄cient peptides.
IC50 values were determined with synthetic peptides. Peptides were
¢rst tested in duplicate between 0.1 WM and 250^500 WM to approx-
imate their IC50 value, and then tested in triplicate at an optimised
range of concentrations.
3. Results and discussion
The entire hydrolysate was ¢rst separated in 10 HPLC frac-
tions, which were tested for ACE inhibitory activity. As seven
of the 10 fractions presented a 20^80% ACE inhibition at 100
WM primary amines (data not shown), an extensive study was
performed on about 40 collected HPLC peptide peaks (Fig.
1a) that were tested at 50 WM primary amines. Results of
ACE inhibition are presented in Fig. 1b. Three peaks (16,
38 and 40) produced an ACE inhibition higher than 70%.
Eight other peaks (8, 17, 18, 19, 35, 37, 39, 41) led to more
than 25% inhibition. The sequence of peptides KS2-CN (f182^
184) (peak 16), KS2-CN (f25^32) (peak 18), KS2-CN (f81^91)
(peak 35), KS2-CN (f174^179) (peak 38), KS2-CN (f81^89)
(peak 39), KS2-CN (f174^181) and KS2-CN (f92^98) (peak
40) was validated by Edman degradation. IC50 values were
determined with corresponding puri¢ed synthetic peptides.
C-terminal KS2-CN (f206^207) (peak 19) was not synthesised
as it also corresponds to L-Lg (f102^103) which has an IC50
value of 122 WM [26].
The methodology used was validated with known inhibi-
tors, captopril, KS1-CN (f23^34) and KS1-CN (f194^199) (Ta-
ble 1). The IC50 values of the synthetic peptides, determined
after logarithmic linearisation (Fig. 2), were in agreement with
the percentage of inhibition obtained at 50 WM primary
amines with natural peptides (Table 1). These peptides were
more active than those described by Maeno et al. [21], which
have IC50 values higher than 300 WM. Moreover, two of these
peptides had an IC50 value lower than 5 WM, namely KS2-CN
(f174^181) and KS2-CN (f174^179), and two others had an
IC50 value of about 15 WM, namely KS2-CN (f92^98) and
KS2-CN (f182^184). These four peptides are among the more
active peptides obtained by an in vitro enzymatic hydrolysis of
milk proteins since their IC50 value is lower than 20 WM [12].
Four of the eight active KS2-CN peptides (KS2-CN (f81^89),
KS2-CN (f92^98), KS2-CN (f174^179) and KS2-CN (f182^184))
resulted from a chymotryptic-like cleavage. Chymotryptic re-
sidual activity has often been reported during tryptic hydro-
lysis [27]. Peptides with an aromatic residue at C-terminal
position would be better inhibitors of ACE than those with
a basic one [28]. Nevertheless, numerous peptides resulting
from speci¢c tryptic activity have been identi¢ed and total
chymotryptic hydrolysates do not systematically appear to
be more active than tryptic ones [29]. Guanidino or O-amino
Table 1
ACE inhibitory activity of bovine KS2-CN-derived peptides
Numbera Inhibitor Inhibition (%)b Amino acid sequence IC50 (WM) Bibliographic IC50 (WM)
Captopril nd 0.022 0.023 [25], 0.018 [47], 0.007 [48]
KS1-CN (f23^34) nd FFVAPFPEVFGK 18 77 [49]
KS1-CN(f194^199) nd TTMPLW 12 16 [50]
18 KS2-CN (f25^32) 42.5 NMAINPSK 60
39 KS2-CN (f 81^89) 32.2 ALNEINQFY 219
35 KS2-CN (f 81^91) 27.2 ALNEINQFYQK 264
40 KS2-CN (f 92^98) 86.0c FPQYLQY 14
38 KS2-CN (f 174^179) 82.7 FALPQY 4.3
40 KS2-CN (f 174^181) 86.0c FALPQYLK 4.3
16 KS2-CN (f 182^184) 70.2 TVY 15
19 KS2-CN (f 206^207) 34.8 YL nd 122 [26]
nd, not determined.
aHPLC peak number in Fig. 1a.
bDetermined with [primary amines] = 50 WM.
cInhibition due to the mixture of KS2-CN (f 92^98) and KS2-CN (f 174^181) in the HPLC peak number 40.
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group of C-terminal basic residue might interact with an
anionic binding site distinct from the catalytic site of ACE
[12].
ACE would be selective with regard to the COOH-terminal
dipeptide sequence of its substrates and inhibitors, with ali-
phatic (V, I, A), basic (R) and aromatic (Y, F) residues being
preferred in penultimate position and aromatic (W, Y, F),
proline and aliphatic (I, A, L, M) residues being preferred
in ultimate position [28]. Surprisingly, KS2-CN (f174^181)
and KS2-CN (f174^179) on the one hand and KS2-CN (f81^
91) and KS2-CN (f81^89) on the other hand had similar IC50
values (Table 1) despite di¡erent C-terminal dipeptides. Here,
the change of the C-terminal dipeptide did not seem to have a
drastic in£uence on the inhibition capacity. Evidence of the
sequential removing of dipeptides from peptide substrate by
ACE has been shown with bradykinin where two successive
C-terminal dipeptides are released [30], suggesting that this
phenomenon might also happen with inhibitors. The possible
degradation of KS2-CN (f174^181) into KS2-CN (f174^179) by
ACE was assayed. Only 2% of the initial quantity of KS2-CN
(f174^181) was hydrolysed in presence or absence of HHL
(Fig. 3). Then, the inhibitory activity of KS2-CN (f174^181)
could not be ascribed to the release of peptide KS2-CN (f174^
179). This type of degradation only concerned 1 or 3% of KS2-
CN (f174^179) in presence or absence of HHL respectively
while it reached 10 or 34% respectively for KS2-CN (f92^98)
despite these two peptides ended with the same C-terminal
dipeptide, QY. Residues from the N-terminal side of the
cleaved bond could interact with critical subsites of ACE.
The weak cleavage of KS2-CN (f174^179) is in agreement
with the fact that ACE is drastically slowed down by the
presence of a proline residue in penultimate or antepenulti-
mate position [31].
N-terminal extension can increase the inhibition potency as
shown by following IC50 values: IYP (61 WM), LIYP (10 WM),
PLIYP (4.4 WM) or LPLP (720 WM), HLPLP (41 WM),
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Fig. 2. Determination of the IC50 value of the more active ACE inhibitors obtained after tryptic hydrolysis of bovine KS2-CN. IC50 values were
obtained after logarithmic linearisation. Each point represents the mean valueWS.E.M. of three independent experiments.
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LHLPLP (2.9 WM) [32]. ACE^inhibitor interactions may ex-
tend beyond the three C-terminal residues. The diversity of
the inhibitors and the absence of known amino acid sequence
recognised by ACE points out the complexity of the inhibitory
mechanism. Several ACE inhibitors have a proline residue in
C-terminal position [32], but this is not su⁄cient or essential
to confer activity [21]. Proline residue at penultimate position
is very unfavourable [28] whereas it is present at antepenulti-
mate position in several inhibitors: YPER, AVPYPQR,
LKPNM, ALPHA and here, NMAINPSK and FALPQY
having IC50 values of 132, 15, 17, 10, 60, and 4.3 WM respec-
tively [16,17,33].
Glutamine and tyrosine residues were present in C-terminal
part of ¢ve from the seven studied peptides. QY and LQAr C-
terminal motives (where Ar is an aromatic amino acid residue)
have already been identi¢ed in ACE inhibitory peptides: KS1-
CN (f136^143) (YYPQIMQY, IC50 = 24.8 WM), KS1-CN
(f164^170) (NNVMLQW, IC50 = 41.0 WM) [17]. Moreover,
VY contained in KS2-CN (f182^184), has a 7 WM IC50 value
[34].
Sour milks or milk protein hydrolysates have been reported
to signi¢cantly decrease blood pressure in spontaneously hy-
pertensive rats [35^42] and in hypertensive humans [43,44]
after a single dose or several weeks of oral administration.
Surprisingly, some of the in vivo very active peptides are
weakly active in vitro (IC50 values comprised between 100
and 1000 WM [36]) and reciprocally. In vivo activation or
loss of activity is perhaps due to further endogenous enzy-
matic cleavage. Interestingly, ¢ve of the seven inhibitors
studied in the present work had a proline residue in various
positions that could protect them from in vivo degradation.
Proline is known to increase resistance to proteolysis [45,46].
Some of the ACE inhibitors identi¢ed here had IC50 values
close to those of the most potent peptides found in milk
proteins hydrolysates. Moreover, KS2-CN (f174^181) and
KS2-CN (f174^179) were in vitro only 200 times less potent
than captopril and were inhibitors for ACE but not substrate.
These peptides and the entire tryptic hydrolysate need to be
tested on spontaneously hypertensive rats to control if their
activity is maintained in vivo.
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